Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus: A Pilot Study
Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus: A Pilot Study
复制标题
DOI：
10.1177/0148607110386378
复制
发表时间：
2011-03-01
影响因子：
3.4
通讯作者：
Fortin, Paul R.
中科院分区：
文献类型：
--
作者：
Aghdassi, Elaheh;Ma, David W. L.;Fortin, Paul R.
前言：循环脂肪酸(FAs)可能在系统性红斑狼疮(SLE)患者的发病机制中起一定作用。目的：比较女性系统性红斑狼疮(SLE)患者与年龄匹配的健康女性(HF)、有心血管病史的SLE患者与无心血管病史的SLE患者(SLE+CVD与SLE-CVD)的红细胞(RBC)和血浆FA的组成，以及(2)采血时接受或未接受强的松治疗的SLE患者之间的红细胞和血浆FA组成。方法：本横断面研究包括33例女性SLE患者(11例SLE+CVD，22例SLE-CVD)和20例心衰对照。测定了患者的人口学特征、心血管疾病风险、用药情况、血液生化指标以及红细胞和血浆总脂的脂肪酸组成。结果：SLE患者的腰围和体重指数均高于HF对照组。这些变量以及血清甘油三酯、血糖和收缩压在SLE+CVD患者中高于SLE-CVD患者。SLE患者RBC FA组分显示二十碳五烯酸(EPA，omega-3活性代谢物)和omega-3指数(EPA+二十二碳六烯酸)低于HF对照组。红细胞炎性代谢物花生四烯酸与抗炎性代谢物EPA的比率在SLE患者中也显著高于HF对照组。SLE组与HF组之间血浆FA水平无明显差异。然而，SLE-CVD患者的血脂谱比SLE+CVD患者更有利。在SLE患者中，强的松的使用导致了RBC和血浆FA成分的改变。结论：SLE患者，无论有无心血管病史，其血浆和红细胞FA成分均发生改变，有利于炎症反应。强的松的使用与FA分布的不同有关。(JPEN J Parenter Enteral Nutr.2011；35：198-208)
Introduction: Circulating fatty acids (FAs) may play a role in the disease pathogenesis of patients with systemic lupus erythematosus (SLE). Objectives: To compare red blood cell (RBC) and plasma FA composition: (1) between female SLE patients and age-matched healthy female (HF) controls and in SLE with history of cardiovascular disease (CVD) and those with no history (SLE+CVD vs SLE-CVD); and (2) between SLE patients who were or were not receiving prednisone treatment at the time of blood sampling. Methods: This cross-sectional study consisted of 33 female patients with SLE (11 SLE+CVD, 22 SLE-CVD) and 20 HF controls. Demographics, CVD risk, medication profile, blood biochemistry, and FA composition of RBC and plasma total lipids were determined. Results: Waist circumference and body mass index were higher in SLE patients than in HF controls. These variables along with serum triglycerides, blood glucose, and systolic blood pressure were higher in SLE+CVD than SLE-CVD patients. RBC FA composition showed lower eicosapentaenoic acid (EPA, omega-3 active metabolite) and omega-3 index (EPA+ docosahexaenoic acid) in SLE patients compared with HF controls. The ratio of the RBC inflammatory metabolite, arachidonic acid, to the anti-inflammatory metabolite EPA was also significantly higher in SLE patients than in HF controls. No differences were seen in plasma FA between SLE and HF groups. However, SLE-CVD patients had a more favorable lipid profile than SLE+CVD patients. In SLE patients, the use of prednisone resulted in alteration of both RBC and plasma FA composition. Conclusion: SLE patients, regardless of their history of CVD, have altered plasma and RBC FA composition favoring inflammation. The use of prednisone was associated with differences in FA profile. (JPEN J Parenter Enteral Nutr. 2011;35:198-208)